Health & Beauty

The 4th China International Import Expo (hereinafter referred to as the CIIE) closed on November 10. In the CIIE under the epidemic, global innovative drugs and cutting-edge medical device technologies have become the focus of attention. Innovative products such as oral drugs for new coronary pneumonia and smart unmanned vaccination systems are all regarded as "big stars."

u3000u3000 The "first show" products in the medical equipment and medicine and health care exhibition area can be called the largest number of products in this year's CIIE, which is dizzying. The quantity and quality of the "New Global, New Asia, New China" products brought by the exhibitors have set new highs in previous years, and the new products and technologies of various first exhibitions far surpass the previous three sessions.

u3000u3000New special drugs bring hope to the treatment of intractable diseases

u3000u3000 This year coincides with the 130th anniversary of the founding of Merck & Co., and it is also the 10th anniversary of the founding of Merck’s China R&D Center. On its open booth of more than 1,000 square meters, the anti-coronavirus oral drug Molnupiravir jointly developed by Merck and Ridgeback has attracted attention from all walks of life. In a phase III study of patients with mild or moderate new coronary pneumonia, the drug obtained a positive interim analysis result, and compared with placebo, the patient's risk of hospitalization or death was reduced by about 50%. Merck plans to seek emergency use authorization in the United States as soon as possible and submit an application to global regulatory agencies.

u3000u3000 As an old friend of the CIIE, Takeda Pharmaceutical, one of the top ten biopharmaceutical companies in the world, this time focused on releasing the world's first and best-in-class innovative products and breakthrough therapies in core areas such as rare diseases of digestive tumors and blood products. In the next 5 years, the company will list more than 15 innovative products in China, and most of them will be first-in-class (first in class) and best-in-class (best-in-class) products, and there will be a large number of them. Drugs for rare diseases also include innovative treatments for tumors and digestive diseases.

u3000u3000 In July this year, GlaxoSmithKline announced the establishment of a national commercial operation center in Pudong, Shanghai. GlaxoSmithKline plans to introduce a series of vaccine products for adults to China in the future, including respiratory syncytial virus (RSV) vaccines and innovative meningitis B vaccines.

u3000u3000 With the advantage of the CIIE platform, pharmaceutical companies from various countries have accelerated the process of registering and listing new drugs in China. It is reported that GlaxoSmithKline's innovative vaccine Xin'anlix (recombinant shingles vaccine) debuted at the CIIE in 2019 and was approved for listing in 2020. It will be exhibited again this year. It will be available in nearly 250 cities in China at an extremely fast rate. Make an appointment for vaccination, covering more than 3800 vaccination points. "Currently, prescription drugs basically adopt the form of simultaneous research and development. As soon as there are new products in the world, China and the United States will simultaneously conduct phase I clinical trials, and at the same time assess whether the drugs under development or the corresponding indications in foreign countries meet the unmet needs of the Chinese market." Ge Said Qi Xin, vice president of Lanxo and general manager of prescription drugs and vaccines in China.

u3000u3000 Roche Pharmaceuticals and Roche Diagnostics under Roche China, occupying a huge booth of thousands of square meters in the “C” area of the medical equipment and healthcare exhibition area. The world’s first broad-spectrum anti-tumor drug for NTRK (neurotrophic tyrosine receptor kinase) and ROS1 (gene rearrangement) developed by it has been included in the "Guangdong-Hong Kong-Macao Greater Bay Area Drugs and Medical Devices Imported Drug List" this year ". Roche has also specially brought 3 innovative rare disease products to assist in the diagnosis and treatment of rare diseases in China.

u3000u3000Incubating Medicine Health Life Science Project

u3000u3000 The driving effect of global mainstream pharmaceutical companies participating in the CIIE has emerged one after another. Multinational giants and domestic parties continue to innovate cooperation models to not only empower China's biomedical industry, but also jointly build a broad Chinese local pharmaceutical R&D ecosystem.

u3000u3000 At present, 18 of the world’s 20 largest pharmaceutical companies and 17 of the world’s top 20 medical devices have established regional headquarters, R&D centers, offices or manufacturing bases in Shanghai, many of which have landed in Zhangjiang, Pudong. Novartis China Life Sciences Open Innovation Platform, Roche China Accelerator, Siemens Medical Shanghai Innovation Center, AstraZeneca Global R&D China Center, etc., which were unveiled this year, have also accelerated the pace of "Made in China to benefit the world."

u3000u3000 At this CIIE, Novartis and Zhangjiang Group signed a memorandum of cooperation on the Novartis China Life Science Open Innovation Platform. It is expected that by the end of 2024, Novartis will submit more than 50 new drug applications in China, and is committed to achieving more than 90% of China's new drug registrations in 2024 with the global synchronization. In the future, Novartis will cooperate with Zhangjiang Group to incubate and accelerate innovative projects in medical and health, life sciences and other fields, and promote the construction of China's biomedical ecosystem. Novartis Group (China) President Badenian stated that Novartis China's life sciences open innovation platform is an important part of its R&D strategic layout and will become a new driving force for its R&D and innovation in China.

u3000u3000 AstraZeneca has launched an internationally leading new drug jointly developed with Hutchison Whampoa Pharmaceuticals. As one of the largest booths in the medical equipment and healthcare exhibition area, AstraZeneca has a total booth area of 1,000 square meters. At present, China has developed into AstraZeneca's second largest market in the world. Prior to this, AstraZeneca reached a contract with its domestic partners through the second and third CIIEs. For example, at the second CIIE, AstraZeneca and CICC Capital jointly established the Global Medical Industry Fund, which has completed the first phase of financing of RMB 2.2 billion and officially entered the target investment stage. In addition, AstraZeneca also signed the 5th CIIE.

u3000u3000 The Expo will make the world resonate with Shanghai. During the 4th CIIE, Lamex Medical, which participated in the exhibition for 4 consecutive years, brought a variety of innovative products, including a special MRI system for newborns, a special MRI system for breast cancer screening, and an ultra-high field small animal research MRI system. And special magnetic resonance for pets. The most concerned one is when Meishi Medical released the world's first "black technology"-COVID-19 ultra-fast new coronavirus detection reagent at the CIIE. Ma Qiyuan, chairman of Lamex Medical, said that this year the company's booth has expanded by 25% compared with last year. The company's original core products are all exhibited, which is the largest number of specialist MRI exhibitors in the past. During the current CIIE, Lamex Medical signed a contract with Singapore’s NEUOME Company and held the world's first release conference of reagent products.